SCREENING NEWBORNS FOR SICKLE CELL DISEASE IN GHANA

Author:

Ohene-Frempong Kwaku1,Oduro Joseph2,Tetteh Hannah2,Nkrumah Francis3

Affiliation:

1. Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

2. Ghana Health Service, Kumasi, Ghana

3. Noguchi Memorial Institute for Medical Research, Legon, Ghana

Abstract

INTRODUCTION: Screening of newborns for sickle cell disease (SCD) allows early initiation of prophylactic therapy, parental education, and comprehensive management, which results in reduced mortality. Since April 1993, a demonstration project to develop and implement a program of newborn screening for SCD has been conducted in Kumasi, Ghana, by the Comprehensive Sickle Cell Center at the Children's Hospital of Philadelphia in collaboration with the Ministry of Health and other institutions in Ghana. OBJECTIVE: Our goal was to assess the program of screening and follow-up of children with SCD in Ghana. METHODS: Infants are screened at birth or at well-infant visits within days or a few weeks after birth. Mothers are asked to come for results within 4 weeks, and failing that, an extensive tracking system is used to deliver results to the homes of families with infants with possible SCD. Tracking relies solely on information obtained from mothers at the time of screening. The goal is to enroll infants with possible SCD into the sickle cell clinic by 8 weeks of age. Pregnant women, parents with children, and the general public are educated regularly about the screening program. Children with SCD receive comprehensive care through the Sickle Cell Clinic at Komfo Anokye Teaching Hospital (Kumasi, Ghana). RESULTS: From February 13, 1995 (when newborn testing was started), to December 31, 2005, a total of 202 244 infants were screened through 8 public health institutions and 14 private clinics in Kumasi and 1 private maternity center and 1 public health Center in Tikrom, a nearby, rural community. A total of 3745 (1.9%) infants were identified as having possible SCD with the following hemoglobin phenotypes according to isoelectric focusing: 2047 (1.04%) fetal sickle cell hemoglobin; 1684 (0.83%) fetal SC hemoglobin; and, 14 (0.003%) fetal SA hemoglobin (Table 1). CONCLUSIONS: Screening and follow-up of newborns for SCD is feasible in a developing country in Africa. Extra effort in tracking is necessary to ensure that infants with disease are found early and referred for medical management. TABLE 1.Screening and Tracking Results: February 1995 to December 2005No.%Total No. of infants screened202 244100.0Infants with possible SCD37451.9 (of infants screened)Under active tracking (newly diagnosed)(125)3.3 (of infants with possible SCD; excluded)Total possible SCD accounted for362096.7 (of infants with possible SCD; reported)Lost to follow-up/never found(494)13.6 (of infants with possible SCD; reported)Dead before contact made(34)0.9 (of infants with possible SCD; reported)No. contacted with results (eligible for enrollment)309285.4 (of infants with possible SCD; reported)    Came for results65121.0 (of those contacted)    Through home visiting244179.0 (of those contacted)Eligible but not enrolled after contact47715.4 (of those eligible)Enrolled in clinic261584.6 (of those eligible)Known deaths after enrollment1094.2 (of those enrolled)

Publisher

American Academy of Pediatrics (AAP)

Subject

Pediatrics, Perinatology, and Child Health

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3